Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results
October 5, 2015 11:03 AM EDTRoth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00), following the announced top-line results for the Phase 3 trial of SPKRPE65. The reported study represents the first successful controlled gene therapy trial. Spark... More
Spark Therapeutics (ONCE) Announces SPK-RPE65 Phase 3 Met Primary Endpoint
October 5, 2015 6:23 AM EDTSpark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs).
The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
There were no serious adverse events related to SPK-RPE65 or deleterious immune responses observed in the trial.... More
